C4X Discovery Holdings PLC Result of General Meeting (8291K)
September 26 2016 - 5:53AM
UK Regulatory
TIDMC4XD
RNS Number : 8291K
C4X Discovery Holdings PLC
26 September 2016
This announcement contains inside information
C4X Discovery Holdings plc
("C4XD" or the "Company")
Result of General Meeting
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug
discovery and development company, today announces that at the
General Meeting held earlier today, all the resolutions put to
shareholders were duly passed.
As a result, the placing announced on 6 September 2016 of
4,901,961 new ordinary shares at 102 pence per ordinary share to
raise GBP5.0 million, is conditional only on Admission which is
expected to take place on 27 September 2016.
Following Admission, the Company's issued share capital will
consist of 37,398,718 ordinary shares. There are no ordinary shares
held in treasury. Therefore, in accordance with the FCA's
Disclosure and Transparency Rule 5.6.1, the Company confirms that
following Admission, the total number of voting rights in the
Company will be 37,398,718.
--ENDS--
For further information please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865803
Zeus Capital Limited
Dan Bate/Phil Walker 0161 831 1512
Dominic Wilson 0203 829 5000
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal, Melissa Gardiner
0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery and development company by exploiting cutting-edge
technologies to design and create best-in-class drug candidates.
The Company has two proprietary and synergistic software platforms
"Taxonomy3(R)" and "Conformetrix" that provide a significant
competitive advantage when combined with an experienced management
team. "Taxonomy3(R)" is a human genetics analysis platform that
utilises a unique mathematical approach to discovery and validation
of drug targets for the treatment of a variety of diseases.
"Conformetrix" determines the 3D shape of drug molecules from
experimental in vitro data that enables the rapid design and
discovery of novel and potent drugs for diseases with high unmet
medical need across broad therapeutic areas. We have a hybrid
business model of wholly-owned programmes and partnerships with
pharma, biotech and academics.
The Company was founded in 2008 as a spin-out from the
University of Manchester and has a highly experienced management
team and Board who have delivered significant value creation within
the healthcare sector historically. For additional information
please go to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
ROMPGUBCBUPQGUQ
(END) Dow Jones Newswires
September 26, 2016 06:53 ET (10:53 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024